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Abstract
Background and aim Over 80% (365/454) of the nation’s centers participated in the Italian Society of Nephrology COVID-
19 Survey. Out of 60,441 surveyed patients, 1368 were infected as of April 23rd, 2020. However, center-specific proportions 
showed substantial heterogeneity. We therefore undertook new analyses to identify explanatory factors, contextual effects, 
and decision rules for infection containment.
Methods We investigated fixed factors and contextual effects by multilevel modeling. Classification and Regression Tree 
(CART) analysis was used to develop decision rules.
Results Increased positivity among hemodialysis patients was predicted by center location [incidence rate ratio (IRR) 1.34, 
95% confidence interval (CI) 1.20–1.51], positive healthcare workers (IRR 1.09, 95% CI 1.02–1.17), test-all policy (IRR 
5.94, 95% CI 3.36–10.45), and infected proportion in the general population (IRR 1.002, 95% CI 1.001–1.003) (all p < 0.01). 
Conversely, lockdown duration exerted a protective effect (IRR 0.95, 95% CI 0.94–0.98) (p < 0.01). The province-contextual 
effects accounted for 10% of the total variability. Predictive factors for peritoneal dialysis and transplant cases were center 
location and infected proportion in the general population. Using recursive partitioning, we identified decision thresholds at 
general population incidence ≥ 229 per 100,000 and at ≥ 3 positive healthcare workers.
Conclusions Beyond fixed risk factors, shared with the general population, the increased and heterogeneous proportion 
of positive patients is related to the center’s testing policy, the number of positive patients and healthcare workers, and to 
contextual effects at the province level. Nephrology centers may adopt simple decision rules to strengthen containment 
measures timely.
Keywords COVID-19 · Renal replacement therapy · Contextual analysis · Classification tree
Introduction
The spread and dynamics of the novel coronavirus disease 
(COVID-19) in Italy posed serious threats to the ability and 
preparedness of nephrology centers to respond to the needs 
of patients on renal replacement therapy (RRT) during the 
exponential phase of the pandemic. At that time, sparse and 
scattered data were available on RRT patients and centers. 
Among the actions taken to provide clinicians and health 
authorities with nationwide data, the Italian Society of 
Nephrology launched a survey to evaluate the spread of 
SARS-CoV-2 in the Nephrology and Dialysis Units [1]. 
The study aimed to estimate the cumulative incidence of 
SARS-CoV-2 positive cases among hemodialysis (HD), 
peritoneal dialysis (PD), and renal transplant (TX) patients. 
It revealed some intriguing findings: higher rates of positive 
cases in HD than in PD and TX patients, and heterogeneous 
spread among Italian regions. The proportion of deceased 
SARS-CoV-2 positive individuals was shockingly high in 
HD patients, and such an unfavorable outcome also occurred 
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more frequently in PD and TX patients than in the general 
population [2, 3].
The pandemic struck RRT centers and patients dramati-
cally, and although specific protocols were soon developed 
and endorsed [4, 5], the absence of effective and evidence-
based treatments left Nephrologists substantially defense-
less. Thus, prevention and meticulous infection control 
remained, and perhaps still remains, the only broadly appli-
cable barrier against SARS-CoV-2 spread and its deadly 
consequences.
The findings of our first article [1] were descriptive in 
nature and elicited three further and newer research issues 
that we address in the present report. First, which are the 
possible explanatory factors for the heterogeneous pro-
portions of SARS-CoV-2 positivity in Italian nephrology 
centers? Second, to what extent is the higher frequency of 
SARS-CoV-2 positivity in HD patients associated with the 
spread of the virus within the dialysis centers? Third, how 
can we translate the survey findings into easily and widely 
applicable clinical decision rules?
To address these specific questions, we designed a “de-
novo” analysis cycle based on multilevel modeling and clas-
sification trees. We used mixed-effect models to identify the 
explanatory factors of the heterogeneous infection spread 
while accounting for the control measures and policies cur-
rently being adopted by each center. Using classification and 
regression trees we sought to develop a simple decision algo-




The Italian Society of Nephrology (SIN) COVID-19 
research group designed a nationwide survey to evaluate the 
impact of the COVID-19 pandemic on nephrology centers 
and patients. Details of the survey design, instruments, and 
procedures can be found in Reference 1. Briefly, on aver-
age, within 11 days, the vast majority [365/454 (80.4%)] 
of invited centers completed and returned the survey ques-
tionnaire, an instrument designed to obtain 17 key pieces 
of information about patients, workforce, and facilities dur-
ing the exponential phase of the COVID-19 pandemic. All 
returned files were checked for consistency and merged in 
the survey database.
Statistical analysis
A preliminary exploratory analysis was performed to detect 
zero inflation in the count of SARS-CoV-2 positive patients 
and subsequent deaths. These latter outcomes were the model 
dependent variables, and the center prevalent patients repre-
sented the exposed population. We then assessed the multivari-
able association with the count SARS-CoV-2 positive cases 
among healthcare workers, and the HD cases admitted to the 
intensive care unit (ICU) as continuous explanatory variables. 
Center testing policies for patients and staff, telephone triage, 
in-person triage, and use of personal protective equipment 
(PPE) entered the models as binary co-variables. Additionally, 
for each center, we derived the number of days elapsed since 
the local lockdown date [6], and the cumulative rate of positive 
cases in the local general population as of April 23rd [7]. Since 
centers are clustered in provinces and provinces in regions, 
three multilevel models were considered. Model 1 included 
provinces as the second level, model 2 included regions as the 
second level, and model 3 provinces nested into regions. We 
used both the multilevel Poisson regression and the multilevel 
negative binomial regression for each model, and we chose the 
best model using the likelihood-ratio (LR) test, when applica-
ble, and the Akaike’s information criterion (AIC).
For the multilevel model, we estimated the variance parti-
tion coefficient (VPC) that is the proportion of variation that 
is beyond what explained by the fixed predictors and informs 
on the existence of a contextual effect [8]. Fixed predictor 
coefficients were exponentiated and reported as cumulative 
incidence rate ratios (IRR) with 95% confidence intervals (CI).
We used Classification and Regression Tree (CART) 
analysis [9–11] to develop a simple and interpretable set of 
rules to support clinical decision making. Tree-based mod-
els are a class of nonparametric algorithms that work by par-
titioning the feature space into a number of non-overlapping 
regions with similar response values using a set of splitting 
rules.
The presence or absence of SARS-CoV-2 positivity was 
the target variable. A tenfold cross-validation method was 
used to evaluate the model reliability. Statistical analyses 
were performed using STATA 15 (StataCorp LLC, TX, 
USA), and R Software Ver 4.0.2 (R Core Team, 2020).
Geospatial analysis
Geographical Information System (GIS) technology was 
used to produce multilevel maps of the model predictions 
on Italian provinces using the Istituto Nazionale di Statistica 
(ISTAT) shapefiles [12]. Geospatial mapping was performed 
using R Software Ver 4.0.2 (R Core Team, 2020).
Results
The SIN COVID Survey Database [1] included data col-
lected from 365 Italian nephrology centers and involved 
30,821 HD, 4139 PD, and 25,481 kidney TX patients, for a 
total of 60,441 RRT patients.
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On April 23rd, 2020, the cumulative incidence of SARS-
CoV-2 positive cases was 3.55% (95% CI 3.34–3.76) in 
HD patients, 1.38% (95% CI 1.04–1.78) in PD patients and 
0.86% (95% CI 0.75–0.98) in TX patients [1]. The distri-
bution of SARS-CoV-2 cases among RRT patients was 
positively skewed (skewness = 5.53), with an average of 3.7 
positive patients per center but with a variance of 88.7 (min 
0; max 105).
Multilevel modeling of SARS‑CoV‑2 positive cases
Multilevel negative binomial regression predicted SARS-
CoV-2 positivity better than multilevel Poisson and zero-
inflated regression (Table 1). The inclusion of random 
effects at the second level significantly improved the model 
fit (χ2 = 3.30, p = 0.034). Among candidate second level var-
iables, the model with provinces as cluster-specific random 
effect had the lowest AIC (Table 1).
The independent factors (Table  2) associated with 
increased rates of SARS-CoV-2 positive HD patients were: 
the geographical latitude of the center (IRR 1.34, 95% CI 
1.20–1.51), the positivity rate in the contextual general 
population (IRR 1.002; 95% CI 1.001–1.003), the count of 
SARS-CoV-2 positive healthcare workers (IRR 1.09; 95% 
CI 1.02–1.17), and the test-all policy for both patients and 
healthcare workers as an interaction term (IRR 5.94, 95% 
CI 3.36–10.45). Conversely, the number of days since the 
lockdown date had a protective effect (IRR 0.95, 95% CI 
0.94–0.98). The second level effect was significant, and the 
contextual effect explained, on average, 10% of the total var-
iability [VPC = 0.10 (range 0.002–0.210)]. The net effect of 
the province as second level variable, holding fixed the first 
level factors, is shown in Fig. 1 and mapped in Fig. 2.
The SARS-CoV-2 positivity rate in PD patients was asso-
ciated with the cumulative incidence of positive cases in the 
province general population (IRR 1.10, 95% CI 1.05–1.20), 
and with geographical latitude of the centers (IRR 1.42, 95% 
CI 1.18–1.70) (Table 3). We found no formal evidence for 
higher-level effects, and the final estimates obtained from a 
conventional negative binomial model are summarized in 
Table 2. For TX patients we found the same associations, 
again with no evidence of a significant contextual effect 
(Table 4).
Classification and regression tree
CART analysis substantially confirmed the predictors identi-
fied by the negative binomial model in the following order 
of importance: geographical latitude of the centers, cumula-
tive incidence of SARS-CoV-2 positive cases in the general 
Table 1  Model selection for 
prediction of SARS-CoV-2 
infection among HD patients
AIC Akaike information criterion, BIC Bayesian information criterion
Model Second level Third level AIC BIC
Poisson regression 1540.02 1571.16
Zero-inflated Poisson regression 1475.54 1510.57
Mixed-effects Poisson regression Province 1221.71 1256.74
Negative binomial regression 1108.27 1143.29
Mixed-effects negative binomial regression Region 1104.78 1143.70
Mixed-effects negative binomial regression Province Region 1102.63 1145.44
Mixed-effects negative binomial regression Province 1100.12 1139.03
Table 2  Independent factors 
associated with the rate of 
SARS-CoV-2 positive cases in 
hemodialysis patients
IRR incidence rate ratio, CI confidence interval, VPC variance partition coefficient, HCWs healthcare 
workers
Factors Units IRR Z p value 95% CI
Geographical latitude 1° 1.34 6.28 < 0.0001 1.20–1.51
Number of positive cases in the 
dialysis centers’ province
100 cases 1.002 2,60 0.009 1.001–1.003
Positive HCWs 1 case 1.09 3.41 0.001 1.02–1.17
Testing all HCWs Yes vs No 1.37 1.30 0.194 0.85 -2.31
Testing all patients Yes vs No 1.67 1.04 0.297 0.64–4.38
Testing all HCWs and patients Yes vs No 5.94 6.12 < 0.0001 3.36–10.45
Days in lockdown 1 day 0.95 − 5.16 < 0.0001 0.94–0.98
Second level random effect
Variance: 0.283 (SE:0.19) VPC = 0.104 Range 0.02–0.21
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population, number of test-positive healthcare workers, and 
days elapsed since lockdown date. The maximally pruned 
model generated three rules (Fig. 3):
1. There were fewer than 1 SARS-CoV-2 positive HD 
patients per center when the cumulative incidence 
of positive cases in the province was below 229 per 
100,000,
2. There were nearly 5 SARS-CoV-2 positive HD patients 
per center when the province cumulative incidence 
of positive cases was greater than or equal to 229 per 
100,000 and there were fewer than 3 test-positive health-
care workers in the center,
3. There were nearly 15 SARS-CoV-2 positive HD patients 
per center when the cumulative incidence of positive 
cases in the province was greater than or equal to 229 
per 100,000 and there were at least 3 test-positive 
healthcare workers in the center.
Fig. 1  Predicted post-estimation 
counts with 95% confidence 
intervals by province and 
ranked from the lowest to the 
highest. Although the variability 
is high, only three provinces are 
significantly different from zero
Fig. 2  Predicted post-estimation count due to the general contextual 
effect at the province level. A negative value indicates that the con-
textual effect reduces the expected count, a near null value indicates 
that the contextual effect is negligible, a positive value suggests an 
increase in the expected count due to the contextual effect
Table 3  Independent factors associated with the rate of SARS-CoV-2 
positive cases in peritoneal dialysis patients
IRR incidence rate ratio, CI confidence interval
Factors Units IRR Z p value 95% CI
Number of positive 
cases in the dialysis 
centers’ province
100 cases 1.10 3.07 0.002 1.05–1.20
Geographical latitude 1° 1.31 3.03 0.002 1.10–1.56
Table 4  Independent factors associated with the rate of SARS-CoV-2 
positive cases in transplant patients
IRR incidence rate ratio, CI confidence interval
Factors Units IRR Z p value 95% CI
Number of positive 
cases in the dialysis 
centers’ province
100 cases 1.30 8.32 < 0.001 1.20–1.33
Geographical latitude 1° 1.42 3.72 < 0.001 1.18–1.70
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Multilevel modelling of case fatality
Admission to ICUs directly influenced the infection fatality 
proportion in SARS-CoV-2 positive HD patients (IRR 1.04; 
95% CI 1.01–1.07), with no evidence of clustering in prov-
inces or regions (χ2 = 0.30, p = 0.58). In PD and TX patients, 
fatality proportions in SARS-CoV-2 positive cases were 
associated with the number of positive cases in the prov-
ince general population (IRR 1.003; 95% CI 1.002–1.004 
for both TX and PD), again with no evidence of clustering 
in provinces or regions (χ2 = 0.02, p = 0.89. and χ2 = 0.04, 
p = 0.84, respectively).
Discussion
The SIN COVID-19 survey was conducted during the 
exponential phase of the pandemic in Italy. At that time, 
there were about 190,000 positive cases in Italy [7], and 
among them, 1093 were HD patients, 57 PD patients, and 
218 kidney transplanted patients. The survey provided three 
main findings [1]: an almost tenfold higher proportion of 
SARS-CoV-2 positive subjects among RRT patients than 
in the general population (2.26 vs 0.3%) with a significant 
difference between HD, PD and TX patients (3.55%, 1.38% 
and 0.86%, respectively); a sizable variability among Italian 
regions with a north to south decreasing gradient; a higher 
case fatality rate among RRT patients than in the general 
population. Beyond these descriptive findings, we undertook 
an extended analysis cycle to identify the independent fac-
tors associated with SARS-CoV-2 spread and subsequent 
death.
We initially classified the factors associated with a higher 
likelihood of SARS-CoV-2 infection in RRT patients into 
three groups. First, factors shared with the general popula-
tion, such as the center location and geographical latitude, 
the local cumulative incidence, and the length of lockdown 
period. Second, factors related to the center, such as the 
number of SARS-CoV-2 positive healthcare workers and 
the testing policy adopted. Third, neighborhood-level con-
textual factors, such as the organizational characteristics of 
the local health authorities.
Main factors and contextual effect
Through April 23rd, 2020, significant spread occurred fol-
lowing a north to south gradient in Italy, which is in keep-
ing with a recent study that included eighty-eight countries 
Cumulative incidence of
positive cases in the province
general population
< 229/100000



















Fig. 3  The decision tree shows the rules and split points to estimate 
the number of SARS-CoV-2 positive patients. The first row in each 
box shows the estimated number of cases, the second row the number 
of patients and the number of centers, the third row the percentage of 
cases covered
 Journal of Nephrology
1 3
reporting a statistically significant correlation between 
country latitude and number of COVID-19 cases [13]. The 
behavior of a seasonal respiratory virus, influenced by tem-
perature, relative humidity, sunlight exposure [14], and air 
pollution [15] that is typical of the industrialized north of 
Italy [16–18], may in part explain such a pattern. On the 
other hand, the national lockdown measures effectively 
reduced infection spread, and resulted in a considerable 
drop in air pollution levels [19]. Hence, the latitude gradi-
ent may actually describe the effects of the lockdown on the 
dynamics of the virus spread. Indeed, the first cases were 
observed in the northern regions, where the infection rap-
idly spread, but the implementation of national lockdown 
measures directly affected the further southwards diffusion 
of the virus.
The number of positive cases observed in each center is 
associated with SARS-CoV-2 spread within the province 
general population. Such finding was somewhat expected 
because it reflects the prior probability that RRT patients 
will be infected before any other specific characteristics or 
condition is considered [20].
The days in lockdown acted as a protective factor and 
showed that quarantine measures effectively reduce the 
number of positive cases and infection spread in vulnerable 
patients. Interestingly, CART analysis identified a split rule 
for lockdown duration over 42 days, corresponding to three 
consecutive 14-day quarantines. This finding is indeed inter-
esting because it suggests that shorter lockdown periods may 
not yield the expected benefit.
Factors related to the center
The greater the number of positive healthcare workers in 
a center, the higher the likelihood of there being SARS-
CoV-2 positive patients. This does not necessarily mean that 
healthcare workers directly infect patients, but it is rather a 
proxy of the virus spread within the center. Notably, through 
CART analysis we found that a threshold of three infected 
healthcare workers can distinguish centers at low risk from 
those at high risk of infection spread when the cumulative 
incidence in the general population exceeds 230 cases per 
100,000 inhabitants.
The test-all policy is associated with increased identi-
fication of SARS-CoV-2 positive cases, especially when 
it is adopted for both healthcare workers and patients. An 
unrestricted testing policy can effectively identify positive 
patients and contain the contagion, especially if the popula-
tion positivity rate is on the rise in the surrounding territory 
[21] because it allows to identify asymptomatic subjects. It 
is however worth pointing out that the testing policy was 
modified in a large number of centers during the course of 
the epidemic. Initially, it was limited to symptomatic cases 
in most centers, but in keeping with the evolving literature 
and recommendations, tests were progressively extended to 
all patients and healthcare workers [22, 23]. Taken together, 
our findings strongly support the universal testing policy, 
advocated by countries that first faced the epidemic [24], 
which is still the topic of a lively debate in most European 
countries.
Contextual factors
Besides the independent effect of the fixed component of 
the model, our analysis provides evidence of a general con-
textual effect. On average, about 10% of the variation in the 
number of positive cases among centers is due to contextual 
differences. Hence, the inherent characteristics of geographi-
cal and administrative areas to which the centers belong (the 
context) explain a sizable part of the variation in positiv-
ity rates. The areas administered by Italian Local Health 
Authorities largely coincide with the province territory. 
Therefore, center policies and resource allocation within the 
same province is determined by the same Authority, which 
may explain the observed discrepancies among strategies 
and timeliness of interventions adopted throughout the coun-
try. For instance, in some provinces, lockdown dates, case 
isolation and management, and directives for containment 
measures and testing varied according to locally determined 
policies. Centralization of HD patients, common in China 
[25], was generally discouraged in Italy, but in some prov-
inces, it was promoted and thus most likely influenced the 
center-specific rates.
We did not find evidence for a contextual effect among 
PD and TX patients and they seem to share the same risk 
factors of the population in the local area. Therefore, pro-
moting home dialysis and kidney transplantation, when pos-
sible, is a valuable and effective containment measure in 
an epidemic context. In this setting, the contextual effect 
especially explores the set of the organizational character-
istics that act beyond the fixed predictors of the outcome, 
but it does not identify each specific characteristic. Further 
analyses should be performed to establish the best organi-
zational set-up.
Differences among RRT modalities
Unlike in-center HD patients, the proportion of SARS-CoV-
2-positive PD and TX patients depends solely on the density 
of cases in the general population and the geographical lati-
tude. It is highly conceivable that patients on home-based 
therapy, with a reduced schedule of center access and a 
higher likelihood of adherence to general prevention meas-
ures, might be less exposed to infection. In other words, 
these patients share the same degree of risk as the general 
population in each local area with no evidence for contextual 
effects.
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Unfortunately, our survey data do not allow to investigate 
the increased immunosuppression-related vulnerability of 
TX patients. As stated in the survey questionnaire [1], we 
collected only information concerning the number of total 
and positive TX patients at the center level and not their indi-
vidual data, such as transplant history, blood chemistry and 
immunosuppressive therapy. Nonetheless, it can be argued 
that any person, be they immunocompetent or immunosup-
pressed, who comes into contact with a formerly unknown 
virus has the same susceptibility to the infection, but the 
consequences are likely to be more severe in immunosup-
pressed organ transplant recipients [26]. The preliminary 
evidence reviewed by Thng [27] supports this hypothesis, 
although further prospective studies are needed to provide 
conclusive data.
Although RRT patients share the same risk of infection 
as the general population, only HD patients show additional 
risks associated with frequent contact with other possibly 
infected patients and healthcare workers. Clearly, our find-
ings do not provide direct evidence of SARS-CoV-2 spread 
within the centers, but they do support this hypothesis. 
Unfortunately, a direct comparison with other groups of 
patients, regularly treated in hospital facilities for chronic 
diseases, is hardly feasible. No other patient population 
undergoes life-saving treatments delivered in the hospital for 
at least 12 h a week, in the same room, with the same fellow 
patients for months or years. Perhaps patients undergoing 
chemotherapy, radiation or physical therapy may somewhat 
resemble HD patients, but most of these treatments were 
either re-scheduled or halted during the critical phase of the 
pandemic [28, 29], consequently they cannot be considered 
a concurrent “control” group.
RRT patients and the general population
The higher proportion of SARS-CoV-2 infection in RRT 
patients as compared to the general population is an arguable 
issue. It is possible that the cumulative number of positive 
cases in the general population provided by national official 
statistics may have underestimated the actual case density 
at the time of the survey. As a matter of fact, the study by 
Lavezzo et al. [21] shows that the cumulative incidence of 
SARS-CoV-2 infection in the population in one of the first 
villages in which the spread occurred in Italy was 2.6% and 
the preliminary data of a survey on SARS-CoV-2 seropreva-
lence in Italy [30] show that it was 2.5%. These findings 
seem numerically consistent with the cumulative incidence 
observed in RRT patients, but they must be interpreted cau-
tiously because biological samples were collected in a small 
municipality in the north-eastern part of the country [21] 
and the seroprevalence was estimated to be less than 1% of 
the Italian population [30].
SARS-CoV-2-positive RRT patients show higher fatality 
rates than the general population [31], regardless of treat-
ment and latitude. In HD patients, there is a link with the 
severity of the disease, expressed by number of ICU admis-
sions, while for PD and TX the fatality rate is associated 
only with the positivity rate in the general population.
Action thresholds
Through CART analysis we identified a simple and inter-
pretable set of rules to support decision making. The deci-
sion tree is a well validated supervised machine learning 
algorithm used for the classification and regression applica-
tion. The pathway illustrated in the decision tree (Fig. 3) 
combines the major determinants of the within-center 
SARS-CoV-2 positivity rate. Namely, the incidence in the 
general population, the area of residence, and a proxy of 
virus spread inside the center (i.e. number of infected health-
care workers). Collectively, the decision rules offer a sim-
ple data-driven response tool to promptly act when the risk 
of infection for the patients becomes critical. Furthermore, 
our results can help policymakers and clinicians’ decisions-
making during the current and future pandemics. Decisions 
are typically made in an evolving scenario and modeling 
becomes a valuable tool to provide guidance for establishing 
prevention strategies and infection control.
Strength and limitations
The main strength of the present survey is that it covers the 
majority of nephrology centers in a nation that was nearly 
overwhelmed by the COVID-19 pandemic, but it must be 
evaluated in the context of its limitations. The findings 
should be interpreted cautiously since the study database 
was based on aggregate data, thus making predictive infer-
ence somewhat imperfect, despite being based on large num-
bers. Furthermore, we were not able to stratify patients and 
outcomes by sex, age, and/or comorbidities because such 
data were not requested in the survey questionnaire.
Conclusions
To the best of our knowledge, this is the largest nationwide 
study on COVID-19 in RRT patients carried out to date [1, 
22, 23], and the present analysis provides answers to the 
questions posed in the Introduction. The local number of 
SARS-CoV-2 positive cases in the general population is 
likely the most important determinant of the infected pro-
portion among RRT patients, but for HD patients other fac-
tors strictly related to in-center models of care contribute 
to explain the higher frequency of positive cases. Namely, 
the number of infected healthcare workers, as a proxy of 
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the virus spread within the dialysis center, and the testing 
policy adopted by the center, especially when it is broad-
ened to include all patients and healthcare workers. These 
factors explain most of the heterogeneity observed in the 
descriptive study [1], while about 10% of the remaining 
variability can be attributed to the contextual organization 
of local healthcare programs. Finally, our study provides 
a novel set of decision rules based on thresholds derived 
from easily accessible and continuously monitored data such 
as the infected proportions in the local general population 
and within the dialysis center. If and when action thresholds 
are crossed, clinicians and policymakers may use them as 
an indication to quickly adopt more stringent containment 
measures beyond those suggested by current guidelines 
[31–33]. Future surveys should use a multi-wave longitu-
dinal design and include more detailed information on both 
center-level and patient-level variables to explain a greater 
proportion of the variability.
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Messina (R. R.Chimenz); Emodialisi Sparviero—Taormina (D. Alfio); 
PO Barone Matteo—Patti (F. Girasole); ADTR Palermo—Palermo (A. 
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